Totus Medicines Inc. announced it has entered into a multi-target research collaboration with Eli Lilly and Company to discover small molecule drug candidates against undisclosed targets. Under the terms of the agreement, Totus Medicines will use its proprietary OmniDEL platform to generate high-quality covalent compounds against Lilly targets. Subsequently, Lilly and Totus will have options to exclusively pursue preclinical and clinical development and commercialization of compounds identified from the collaboration and receive milestone payments.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
820.3 USD | +0.65% | +1.60% | +40.73% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Totus Medicines Inc. Announces Strategic Multi-Target Research Collaboration with Eli Lilly and Company